## MDT Regimen Distinction: MB vs. PB Based on Bacillary Index ### Clinical Scenario Analysis The patient has: - **BI = 4+** → Clearly **multibacillary (MB)** leprosy - Multiple skin lesions (8) → Consistent with MB - No mention of severe deformity or complications → Standard MB regimen applies **Key Point:** The **duration of supervised MDT** is the cardinal distinguishing feature between PB and MB regimens. ### WHO MDT Regimen Comparison | Parameter | PB Leprosy | MB Leprosy | |-----------|-----------|----------| | **BI threshold** | ≤ 2+ | ≥ 3+ | | **Supervised duration** | **6 months** | **12 months** | | **Unsupervised duration** | 6 months | 12 months | | **Rifampicin** | 600 mg monthly | 600 mg monthly (same dose) | | **Dapsone** | 100 mg daily | 100 mg daily (same dose) | | **Clofazimine** | 300 mg monthly + 50 mg daily | 300 mg monthly + 50 mg daily | | **Total drug load** | Lower | Higher (due to 12-month duration) | | **Infectivity after 1st dose** | Non-infectious | Remains infectious for ~2 weeks | **High-Yield:** The **drug composition is identical** between PB and MB regimens; what differs is the **duration** (6 vs. 12 months). ### Why 12 Months for MB? 1. **Bacillary burden**: BI ≥ 3+ indicates high viable bacillary load; 6 months is insufficient for sterilization. 2. **Relapse prevention**: 12-month MDT reduces relapse risk in MB patients to <1%. 3. **Public health**: Longer supervised therapy ensures compliance and reduces transmission risk. 4. **WHO guideline**: All international leprosy programs use this standard. **Clinical Pearl:** A patient completing 6-month MDT with BI = 4+ is **at high risk of relapse** and represents **treatment failure**, not cure. **Mnemonic:** **"MB = More Months (12); PB = Paltry Months (6)"** [cite:Park 26e Ch 8] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.